You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Retrovirus

Showing 1 - 25 of 164
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Simplified Treatment of Anti-retrovirus in China (C-STAR)

Recruiting
  • HIV/AIDS
  • Guangzhou, Guangdong, China
    Guangzhou 8th People's Hospital
Jul 19, 2021

Solid and Hematological Malignancies Trial in United States (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, KITE-585)

Enrolling by invitation
  • Solid and Hematological Malignancies
  • Axicabtagene Ciloleucel
  • Brexucabtagene Autoleucel (KTE-X19)
  • Duarte, California
  • +7 more
Jun 29, 2022

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB Trial in Redwood City, Worcester (EB-101 Surgical

Not yet recruiting
  • Epidermolysis Bullosa
  • +2 more
  • EB-101 Surgical application of RDEB wounds
  • Redwood City, California
  • +1 more
Feb 13, 2023

Deep Full-thickness Burn Injury (Disorder) Trial in Augusta, Boston (Xeno-Skin™, Human Cadaver Allograft)

Completed
  • Deep Full-thickness Burn Injury (Disorder)
  • Xeno-Skin™
  • Human Cadaver Allograft
  • Augusta, Georgia
  • +1 more
Jun 28, 2022

Acute Myeloid Leukemia, Multiple Myeloma Trial in Ostrava, Milan, Roma (MLM-CAR44.1 T-cells at day 0 Single intravenous

Terminated
Has Results
  • Acute Myeloid Leukemia
  • Multiple Myeloma
  • MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
  • Ostrava, Czech Republic, Czechia
  • +2 more
Dec 20, 2021

Long-Term Follow-Up of Recipient of Gene Transfer Research

Recruiting
  • Retroviridae Infections
  • Cancer
  • Blood Tests
  • Questionnaires
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 22, 2022

HIV, Cytopenias Trial in Buffalo (Zidovudine, Sargramostim)

Completed
  • HIV Infections
  • Cytopenias
  • Buffalo, New York
    SUNY / Erie County Med Ctr at Buffalo
Oct 27, 2021

Allogeneic Gamma Delta (?d) CAR T Cells

Enrolling by invitation
  • Lymphoma, Follicular
  • +5 more
  • ADI-001
  • Stanford, California
  • +4 more
Jun 7, 2022

Glioblastoma, Gliosarcoma Trial in Seattle (radiation, procedure, drug, biological, other)

Completed
Has Results
  • Glioblastoma
  • Gliosarcoma
  • 3-Dimensional Conformal Radiation Therapy
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Mar 4, 2022

HIV Trial in United States (Zidovudine, Zalcitabine)

Completed
  • HIV Infections
  • Los Angeles, California
  • +6 more
Oct 27, 2021

Multiple Sclerosis Trial in Stockholm (Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg)

Terminated
  • Multiple Sclerosis
  • Temelimab 18 mg/kg
  • +2 more
  • Stockholm, Sweden
    Center for Neurology, Academic Specialist Center
Jul 4, 2022

Multiple Myeloma, Immune System Diseases Trial in Chapel Hill (CAR138 T Cells)

Recruiting
  • Multiple Myeloma
  • Immune System Diseases
  • CAR138 T Cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jan 10, 2023

Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)

Completed
  • Multiple Sclerosis
  • temelimab 18 mg/kg
  • +3 more
  • Stockholm, Sweden
    Center for Neurology, Academic Specialist Center
Jul 4, 2022

Tissue Biopsy and Imaging Studies in HIV-Infected Patients

Recruiting
  • HIV
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Ovarian Cancer Trial (Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in

    Not yet recruiting
    • Ovarian Cancer
    • Autologous genetically modified ADP-A2M4CD8 cells
    • Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
    • (no location specified)
    Jan 31, 2023

    Study of Transfusion-Transmitted Infections

    Completed
    • Viral Disease
    • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 25, 2023

      Multiple Sclerosis Trial in Basel, Geneva (GNbAC1, GNbAC1 )

      Completed
      • Multiple Sclerosis
      • GNbAC1
      • GNbAC1 placebo
      • Basel, Switzerland
      • +1 more
      Feb 5, 2021

      Post-COVID-19 Syndrome Trial in Geneva (Temelimab 54mg/kg, Placebo)

      Not yet recruiting
      • Post-COVID-19 Syndrome
      • Temelimab 54mg/kg
      • Placebo
      • Geneva, Switzerland
        Geneva University Hospital
      Aug 9, 2022

      Hepatocellular Carcinoma, Metastatic Cancer Trial in Makati City, Pasig City, Quezon City (GEN2 (HSV-Thymidine Kinase-m2 and

      Recruiting
      • Hepatocellular Carcinoma
      • Metastatic Cancer
      • GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
      • Makati City, Philippines
      • +3 more
      Mar 14, 2022

      Microbiome of Donor Iron Deficient Study

      Completed
      • Iron Deficiency
        • New York, New York
          Columbia University Irving Medical Center
        Sep 15, 2022

        Bipolar Disorder, Schizophrenia Trial in France (Blood sampling)

        Recruiting
        • Bipolar Disorder
        • Schizophrenia
        • Blood sampling
        • Bordeaux, France
        • +5 more
        Jul 26, 2022

        Diabetes Type 1 Trial in Australia (GNbAC1, Placebo)

        Completed
        • Diabetes Mellitus Type 1
        • Macquarie University, New South Wales, Australia
        • +12 more
        Oct 19, 2020

        Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Worcester (EB-101)

        Active, not recruiting
        • Epidermolysis Bullosa
        • Recessive Dystrophic Epidermolysis Bullosa
        • EB-101
        • Redwood City, California
        • +1 more
        Apr 5, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (GNbAC1, Placebo)

        Completed
        • Multiple Sclerosis, Relapsing-Remitting
        • Sofia, Bulgaria
        • +11 more
        Oct 19, 2020

        Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)

        Recruiting
        • Recurrent Glioblastoma
        • Refractory Glioblastoma
        • Hangzhou, Zhejiang, China
        • +2 more
        Dec 25, 2022